RxDoctor Payments Data

Harold Thomas, MD

Internal Medicine · Amory, MSNPI 1811953888

Payments from drug & device makers

$1,626in general payments, 2019–2025

Across 136 payments — averaging $11.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$550
  • AbbVie$397
  • Daiichi Sankyo Inc.$145
  • Otsuka America Pharmaceutical, Inc.$101
  • AstraZeneca$74
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$56
  • plus $305 from 15 others

What the payments were for

  • Food & beverage$1,61899%
  • Education$91%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,626 in reported general payments places this provider in the 70th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$249,330
Medicare patients
467
Services billed
5,711

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide182$226,979
EliquisApixaban396$194,502
JanuviaSitagliptin Phosphate278$140,433
FarxigaDapagliflozin Propanediol164$114,508
JardianceEmpagliflozin112$99,482
LinzessLinaclotide136$78,530
XolairOmalizumab12$69,592
Tresiba Flextouch U-200Insulin Degludec53$57,198
MounjaroTirzepatide44$48,950
XareltoRivaroxaban99$46,333
TradjentaLinagliptin78$43,076
Janumet XrSitagliptin Phos/Metformin Hcl39$41,577
TrintellixVortioxetine Hydrobromide50$26,262
Tetrabenazine21$24,941
RybelsusSemaglutide21$24,125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$550$251,104203 claims
MerckJanuvia, Janumet Xr$16$182,009317 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy$22$150,295202 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$74$142,438218 claims
AbbVieLinzess$397$78,530136 claims
Lilly USA, LLCMounjaro, Trulicity$23$65,86655 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$31$26,26250 claims
GSKTrelegy Ellipta, Breo Ellipta$12$24,59944 claims
NovartisEntresto$14$16,79415 claims
Astellas Pharma US IncMyrbetriq$18$11,58826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Amory

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →